PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Anixa Biosciences, Inc. (ANIX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS03528H1095
CUSIP03528H109
SectorHealthcare
IndustryDiagnostics & Research

Highlights

Market Cap$90.91M
EPS-$0.34
Revenue (TTM)$210.00K
Gross Profit (TTM)$127.50K
EBITDA (TTM)-$13.10M
Year Range$2.75 - $5.13
Target Price$12.00
Short %3.31%
Short Ratio6.01

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Anixa Biosciences, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Anixa Biosciences, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%1,000.00%2,000.00%3,000.00%December2024FebruaryMarchAprilMay
-94.84%
3,056.61%
ANIX (Anixa Biosciences, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Anixa Biosciences, Inc. had a return of -29.64% year-to-date (YTD) and -20.87% in the last 12 months. Over the past 10 years, Anixa Biosciences, Inc. had an annualized return of -10.31%, while the S&P 500 had an annualized return of 10.87%, indicating that Anixa Biosciences, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-29.64%11.56%
1 month-12.50%7.13%
6 months-5.86%17.26%
1 year-20.87%26.92%
5 years (annualized)-7.96%13.56%
10 years (annualized)-10.31%10.87%

Monthly Returns

The table below presents the monthly returns of ANIX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202417.01%-22.91%-10.86%-4.81%-29.64%
20232.82%1.14%-2.71%-5.12%-25.00%4.58%12.19%2.23%-10.90%-3.36%5.70%16.17%-8.71%
202210.44%-15.24%-1.44%18.61%10.46%-14.76%24.18%9.74%17.99%13.82%-10.00%-15.67%43.10%
202118.89%38.63%-7.51%4.27%-18.65%-2.27%13.92%26.70%-14.82%-0.00%-23.69%-18.41%-3.26%
20208.23%-15.77%-46.82%18.87%20.63%34.21%-9.15%-28.78%22.73%-15.23%28.16%16.29%-6.40%
201930.20%-1.36%-10.67%-7.96%0.24%-12.95%29.20%-15.32%0.72%-3.25%-1.03%-14.36%-16.75%
201858.05%-11.80%16.72%-2.86%-5.63%-13.92%8.58%15.81%21.78%-12.72%-3.21%0.51%66.95%
2017-9.26%-19.39%-24.05%-35.00%-56.92%36.90%-31.30%-15.06%291.95%-22.05%21.95%-5.60%-56.30%
2016-2.33%-21.09%29.74%-6.31%14.89%-3.09%1.27%27.67%-4.19%63.24%-10.24%-5.26%79.40%
2015-2.73%-10.09%37.32%-9.16%8.33%23.08%22.25%-14.31%13.37%-21.68%-24.46%7.12%9.45%
2014108.89%-24.41%0.00%13.33%-13.24%1.69%-13.67%2.70%-9.77%-16.67%-15.00%-35.29%-42.11%
201333.33%-12.50%-4.76%14.00%44.74%-16.67%-20.73%-0.00%-12.80%2.58%7.18%-9.09%5.56%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ANIX is 27, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.


The Risk-Adjusted Performance Rank of ANIX is 2727
ANIX (Anixa Biosciences, Inc.)
The Sharpe Ratio Rank of ANIX is 2828Sharpe Ratio Rank
The Sortino Ratio Rank of ANIX is 2828Sortino Ratio Rank
The Omega Ratio Rank of ANIX is 2929Omega Ratio Rank
The Calmar Ratio Rank of ANIX is 3131Calmar Ratio Rank
The Martin Ratio Rank of ANIX is 2020Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Anixa Biosciences, Inc. (ANIX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ANIX
Sharpe ratio
The chart of Sharpe ratio for ANIX, currently valued at -0.34, compared to the broader market-2.00-1.000.001.002.003.004.00-0.34
Sortino ratio
The chart of Sortino ratio for ANIX, currently valued at -0.11, compared to the broader market-4.00-2.000.002.004.006.00-0.11
Omega ratio
The chart of Omega ratio for ANIX, currently valued at 0.99, compared to the broader market0.501.001.502.000.99
Calmar ratio
The chart of Calmar ratio for ANIX, currently valued at -0.22, compared to the broader market0.002.004.006.00-0.22
Martin ratio
The chart of Martin ratio for ANIX, currently valued at -1.01, compared to the broader market-10.000.0010.0020.0030.00-1.01
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.34, compared to the broader market-2.00-1.000.001.002.003.004.002.34
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.31, compared to the broader market-4.00-2.000.002.004.006.003.31
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.41, compared to the broader market0.501.001.502.001.41
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.90, compared to the broader market0.002.004.006.001.90
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.93, compared to the broader market-10.000.0010.0020.0030.008.93

Sharpe Ratio

The current Anixa Biosciences, Inc. Sharpe ratio is -0.34. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Anixa Biosciences, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00December2024FebruaryMarchAprilMay
-0.34
2.34
ANIX (Anixa Biosciences, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Anixa Biosciences, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%December2024FebruaryMarchAprilMay
-98.87%
0
ANIX (Anixa Biosciences, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Anixa Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Anixa Biosciences, Inc. was 99.75%, occurring on Aug 15, 2017. The portfolio has not yet recovered.

The current Anixa Biosciences, Inc. drawdown is 98.87%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.75%Jun 14, 19965304Aug 15, 2017
-76.47%Jul 13, 1993292Sep 6, 1994448Jun 13, 1996740
-71.15%Apr 8, 1987148Nov 5, 1987300Jan 13, 1989448
-68.83%Feb 3, 198642Apr 3, 1986256Apr 7, 1987298
-64.47%Jan 25, 1989400Aug 23, 1990120Feb 13, 1991520

Volatility

Volatility Chart

The current Anixa Biosciences, Inc. volatility is 17.87%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%December2024FebruaryMarchAprilMay
17.87%
3.10%
ANIX (Anixa Biosciences, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Anixa Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items